Human prion disorders (transmissible spongiform encephalopathies, TSEs) are unique, progressive, and fatal neurodegenerative diseases caused by aggregation of misfolded prion protein in neuronal tissue. Due to the potential transmission, human TSEs are under active surveillance in a majority of countries; in the Czech Republic data are centralized at the National surveillance center (NRL) which has a clinical and a neuropathological subdivision. The aim of our article is to review current knowledge about human TSEs and summarize the experience of active surveillance of human prion diseases in the Czech Republic during the last 20 years. Possible or probable TSEs undergo a mandatory autopsy using a standardized protocol. From 2001 to 2020, 305 cases of sporadic and genetic TSEs including 8 rare cases of Gerstmann-Sträussler-Scheinker syndrome (GSS) were confirmed. Additionally, in the Czech Republic, brain samples from all corneal donors have been tested by the NRL immunology laboratory to increase the safety of corneal transplants since January 2007. All tested 6590 corneal donor brain tissue samples were negative for prion protein deposits. Moreover, the routine use of diagnostic criteria including biomarkers are robust enough, and not even the COVID-19 pandemic has negatively impacted TSEs surveillance in the Czech Republic.

Department of Neurology 3rd Faculty of Medicine Charles University and Thomayer University Hospital 14059 Prague Czech Republic

Department of Pathology 1st Faculty of Medicine Charles University and General University Hospital 12800 Prague Czech Republic

Department of Pathology 3rd Faculty of Medicine Charles University and University Hospital Kralovske Vinohrady 10034 Prague Czech Republic

Department of Pathology and Molecular Medicine 3rd Faculty of Medicine Charles University and Thomayer University Hospital 14059 Prague Czech Republic

Zobrazit více v PubMed

Imran M., Mahmood S. An overview of human prion diseases. Virol. J. 2011;8:559. doi: 10.1186/1743-422X-8-559. PubMed DOI PMC

Asher D.M., Gregori L. Human transmissible spongiform encephalopathies: Historic view. Handb. Clin. Neurol. 2018;153:1–17. PubMed

Kuwahara C., Takeuchi A.M., Nishimura T., Haraguchi K., Kubosaki A., Matsumoto Y., Saeki K., Matsumoto Y., Yokoyama T., Itohara S., et al. Prions prevent neuronal cell-line death. Nature. 1999;400:225–226. doi: 10.1038/22241. PubMed DOI

Wulf M.A., Senatore A., Aguzzi A. The biological function of the cellular prion protein: An update. BMC Biol. 2017;15:34. doi: 10.1186/s12915-017-0375-5. PubMed DOI PMC

Chiesa R., Harris D.A. Fishing for prion protein function. PLoS Biol. 2009;7:e75. doi: 10.1371/journal.pbio.1000075. PubMed DOI PMC

Steele A.D., Lindquist S., Aguzzi A. The prion protein knockout mouse: A phenotype under challenge. Prion. 2007;1:83–93. doi: 10.4161/pri.1.2.4346. PubMed DOI PMC

Linden R., Martins V.R., Prado M.A., Cammarota M., Izquierdo I., Brentani R.R. Physiology of the prion protein. Physiol. Rev. 2008;88:673–728. doi: 10.1152/physrev.00007.2007. PubMed DOI

McLennan N.F., Brennan P.M., McNeill A., Davies I., Fotheringham A., Rennison K.A., Ritchie D., Brannan F., Head M.W., Ironside J.W., et al. Prion protein accumulation and neuro-protection in hypoxic brain damage. Am. J. Pathol. 2004;165:227–235. doi: 10.1016/S0002-9440(10)63291-9. PubMed DOI PMC

Spudich A., Frigg R., Kilic E., Kilic U., Oesch B., Raeber A., Bassetti C.L., Hermann D.M. Aggravation of ischemic brain injury by prion protein deficiency: Role of ERK-1/-2 and STAT-1. Neurobiol. Dis. 2005;20:442–449. doi: 10.1016/j.nbd.2005.04.002. PubMed DOI

Prusiner S.B. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216:136–144. doi: 10.1126/science.6801762. PubMed DOI

Prusiner S.B. Prions. Proc. Natl. Acad. Sci. USA. 1998;95:13363–13383. doi: 10.1073/pnas.95.23.13363. PubMed DOI PMC

Wolschner C., Giese A., Kretzschmar H.A., Huber R., Moroder L., Budisa N. Design of anti- and pro-aggregation variants to assess the effects of methionine oxidation in human prion protein. Proc. Natl. Acad. Sci. USA. 2009;106:7756–7761. doi: 10.1073/pnas.0902688106. PubMed DOI PMC

Nelson R., Eisenberg D. Recent atomic models of amyloid fibril structure. Curr. Opin. Struct. Biol. 2006;16:260–265. doi: 10.1016/j.sbi.2006.03.007. PubMed DOI

Pastore A., Zagari A. A structural overview of the vertebrate prion proteins. Prion. 2007;1:185–197. doi: 10.4161/pri.1.3.5281. PubMed DOI PMC

Sikorska B., Knight R., Ironside J.W., Liberski P.P. Creutzfeldt-Jakob disease. Adv. Exp. Med. Biol. 2012;724:76–90. PubMed

Vacca V.M., Jr. CJD: Understanding Creutzfeldt-Jakob disease. Nursing. 2016;46:36–43. doi: 10.1097/01.NURSE.0000480598.84274.0f. PubMed DOI

Gençer A.G., Pelin Z., Küçükali C.İ., Topçuoğlu O.B., Yilmaz N. Creutzfeldt-Jakob disease. Psychogeriatrics. 2011;11:119–124. doi: 10.1111/j.1479-8301.2011.00361.x. PubMed DOI

Creutzfeld H.G. Über eine eigenartige herdförmige Erkrankung des Zentralnervensystems. Z. Ges. Neurol. Psychiatr. 1920;57:1–18. doi: 10.1007/BF02866081. DOI

Jakob A. Über eine eigenartige Erkrankung des Zentral-nervensystems mit bemerkenswertem anatomischem Befunde (spastische pseudosklerotische Encephalomyelopathie mit disseminierten Degenerationsherden) Dtsch. Z. Nervenheilk. 1921;70:132–146.

Jakob A. Über eigenartige Erkrankrungen des Zentralnervensystems mit bemerkenswerten anatomischen Befunden (Spastische Pseudosklerose—Enzephalomyelopathie mit disseminierten Degenerationsherden) Z. Ges. Neurol. Psychiatr. 1921;64:147–228. doi: 10.1007/BF02870932. DOI

Jakob A. Über eine der multiplen Sklerose klinisch nahestehende Erkrankung des Zentralnervensystems (spastische Pseudoskerlose) mit bemerkenswertem anatomischem Befunde. Mitteilung eines vierten Falles. Med. Klin. 1921;17:372–376.

Liberski P.P. Kuru: A journey back in time from papua new Guinea to the neanderthals’ extinction. Pathogens. 2013;2:472–505. doi: 10.3390/pathogens2030472. PubMed DOI PMC

Will R.G., Ironside J.W., Zeidler M., Cousens S.N., Estibeiro K., Alperovitch A., Poser S., Pocchiari M., Hofman A., Smith P.G. A new variant of Creutzfeldt- Jakob disease in the UK. Lancet. 1996;347:921. doi: 10.1016/S0140-6736(96)91412-9. PubMed DOI

Hill A.F., Desbruslais M., Joiner S., Sidle K.C., Gowland I., Collinge J., Doey L.J., Lantos P. The same prion strain causes vCJD and BSE. Nature. 1997;389:448–526. doi: 10.1038/38925. PubMed DOI

The national CJD research and surveillance unit The University of Edinburgh. [(accessed on 9 September 2021)]. Available online: https://www.cjd.ed.ac.uk/surveillance.

Brandel J.P., Vlaicu M.B., Culeux A., Belondrade M., Bougard D., Grznarova K., Denouel A., Plu I., Bouaziz-Amar E., Seilhean D., et al. Variant Creutzfeldt-Jakob Disease Diagnosed 7.5 Years after Occupational Exposure. N. Engl. J. Med. 2020;383:83–85. doi: 10.1056/NEJMc2000687. PubMed DOI

France Issues Moratorium on Prion Research after Fatal Brain Disease Strikes Two Lab Workers. Science. [(accessed on 9 September 2021)]. Available online: https://www.science.org/news/2021/07/france-issues-moratorium-prion-research-after-fatal-brain-disease-strikes-two-lab.

Budka H., Aguzzi A., Brown P., Brucher J.M., Bugiani O., Gullotta F., Haltia N., Hauw J.J., Ironside J.W., Jellinger K., et al. Neuropathological Diagnostic Criteria for Creutzfeldt-Jakob Disease (CJD) and Other Human Spongiform Encephalopathies (Prion Diseases) Brain Pathol. 1995;5:459–466. doi: 10.1111/j.1750-3639.1995.tb00625.x. PubMed DOI

Bell J.E., Ironside J.W. Neuropathology of spongiform encephalopathies in humans. Br. Med. Bull. 1993;49:738–777. doi: 10.1093/oxfordjournals.bmb.a072645. PubMed DOI

Collinge J. Variant Creutzfeldt-Jakob disease. Lancet. 1999;354:317–323. doi: 10.1016/S0140-6736(99)05128-4. PubMed DOI

Hill A.F., Joiner S., Wadsworth J.D.F., Sidle K.C.L., Bell J.E., Budka H., Ironside J.W., Collinge J. Molecular classification of sporadic Creutzfeldt–Jakob disease. Brain. 2003;126:1333–1346. doi: 10.1093/brain/awg125. PubMed DOI

Parchi P., Giese A., Capellari S., Brown P., Schulz-Schaeffer W., Windl O., Zerr I., Budka H., Kopp N., Piccardo P., et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann. Neurol. 1999;46:224–233. doi: 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W. PubMed DOI

Brown P., Cathala F., Raubertas R.F., Gajdusek D.C., Castaigne P. The epidemiology of Creutzfeldt–Jakob disease: Conclusion of a 15-year investigation in France and review of the world literature. Neurology. 1987;37:895–904. doi: 10.1212/WNL.37.6.895. PubMed DOI

Uttley L., Carroll C., Wong R., Hilton D.A., Stevenson M. Creutzfeldt-Jakob disease: A systematic review of global incidence, prevalence, infectivity, and incubation. Lancet Infect Dis. 2020;20:e2–e10. doi: 10.1016/S1473-3099(19)30615-2. PubMed DOI

Manix M., Kalakoti P., Henry M., Thakur J., Menger R., Guthikonda B., Nanda A. Creutzfeldt-Jakob disease: Updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy. Neurosurg. Focus. 2015;39:E2. doi: 10.3171/2015.8.FOCUS15328. PubMed DOI

Watson N., Brandel J.P., Green A., Hermann P., Ladogana A., Lindsay T., Mackenzie J., Pocchiari M., Smith C., Zerr I., et al. The importance of ongoing international surveillance for Creutzfeldt–Jakob disease. Nat. Rev. Neurol. 2021;17:362–379. doi: 10.1038/s41582-021-00488-7. PubMed DOI PMC

Rudge P., Hyare H., Green A., Collinge J., Mead S. Imaging and CSF analyses effectively distinguish CJD from its mimics. J. Neurol. Neurosurg. Psychiatry. 2018;89:461–466. doi: 10.1136/jnnp-2017-316853. PubMed DOI PMC

Bizzi A., Pascuzzo R., Blevins J., Grisoli M., Lodi R., Moscatelli M.E.M., Castelli G., Cohen M.L., Schonberger L.B., Foutz A., et al. Evaluation of a New Criterion for Detecting Prion Disease with Diffusion Magnetic Resonance Imaging. JAMA Neurol. 2020;77:1141–1149. doi: 10.1001/jamaneurol.2020.1319. PubMed DOI PMC

Wieser H.G., Schindler K., Zumsteg D. EEG in Creutzfeldt-Jakob disease. Clin Neurophysiol. 2006;117:935–951. doi: 10.1016/j.clinph.2005.12.007. PubMed DOI

Steinhoff B.J., Räcker S., Herrendorf G., Poser S., Grosche S., Zerr I., Kretzschmar H., Weber T. Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease. Arch. Neurol. 1996;53:162–166. doi: 10.1001/archneur.1996.00550020074017. PubMed DOI

Centers for Disease Control and Prevention: CDC’s Diagnostic Criteria for Creutzfeldt-Jakob Disease (CJD) [(accessed on 6 January 2021)];2018 Available online: https://www.cdc.gov/prions/cjd/diagnostic-criteria.html.

Mader E.C., Jr., El-Abassi R., Villemarette-Pittman N.R., Santana-Gould L., Olejniczak P.W., England J.D. Sporadic Creutzfeldt-Jakob disease with focal findings: Caveats to current diagnostic criteria. Neurol. Int. 2013;5:e1. doi: 10.4081/ni.2013.e1. PubMed DOI PMC

Heinemann U., Krasnianski A., Meissner B., Kallenberg K., Kretzschmar H.A., Schulz-Schaeffer W. Brain biopsy in patients with suspected Creutzfeldt-Jakob disease. J. Neurosurg. 2008;109:735–741. doi: 10.3171/JNS/2008/109/10/0735. PubMed DOI

Cracco L., Appleby B.S., Gambetti P. Handbook of Clinical Neurology. Volume 153. Elsevier; Amsterdam, The Netherlands: 2018. Chapter 15: Fatal familial insomnia and sporadic fatal insomnia; pp. 175–190. PubMed DOI

Lugaresi E., Medori R., Montagna P., Baruzzi A., Cortelli P., Lugaresi A., Tinuper P., Zucconi M., Gambetti P. Fatal familial insomnia and dysautonomia with selective degeneration of thalamic nuclei. N. Engl. J Med. 1986;315:997–1003. doi: 10.1056/NEJM198610163151605. PubMed DOI

Montagna P., Gambetti P., Cortelli P., Lugaresi E. Familial and sporadic fatal insomnia. Lancet Neurol. 2003;2:167–176. doi: 10.1016/S1474-4422(03)00323-5. PubMed DOI

Mehta L.R., Huddleston B.J., Skalabrin E.J., Burns J.B., Zou W.Q., Gambetti P., Chin S.S. Sporadic fatal insomnia masquerading as a paraneoplastic cerebellar syndrome. Arch Neurol. 2008;65:971–973. doi: 10.1001/archneur.65.7.971. PubMed DOI

Moda F., Suardi S., Di Fede G., Indaco A., Limido L., Vimercati C., Ruggerone M., Campagnani I., Langeveld J., Terruzzi A., et al. MM2-thalamic Creutzfeldt-Jakob disease: Neuropathological, biochemical and transmission studies identify a distinctive prion strain. Brain Pathol. 2012;22:662–669. doi: 10.1111/j.1750-3639.2012.00572.x. PubMed DOI PMC

Piao Y.S., Kakita A., Watanabe H., Kitamoto T., Takahashi H. Sporadic fatal insomnia with spongiform degeneration in the thalamus and widespread PrPSc deposits in the brain. Neuropathology. 2005;25:144–149. doi: 10.1111/j.1440-1789.2005.00608.x. PubMed DOI

Parchi P., Capellari S., Chin S., Schwarz H.B., Schecter N.P., Butts J.D., Hudkins P., Burns D.K., Powers J.M., Gambetti P. A subtype of sporadic prion disease mimicking fatal familial insomnia. Neurology. 1999;52:1757–1763. doi: 10.1212/WNL.52.9.1757. PubMed DOI

Mastrianni J.A., Nixon R., Layzer R., Telling G.C., Han D., DeArmond S.J. Prion protein conformation in a patient with sporadic fatal insomnia. N. Engl. J. Med. 1999;340:1630–1638. doi: 10.1056/NEJM199905273402104. PubMed DOI

Gambetti P., Dong Z., Yuan J., Xiao X., Zheng M., Alshekhlee A., Castellani R., Cohen M., Barria M.A., Gonzalez-Romero D., et al. A novel human disease with abnormal prion protein sensitive to protease. Ann. Neurol. 2008;63:697–708. doi: 10.1002/ana.21420. PubMed DOI PMC

Notari S., Appleby B.S., Gambetti P. Chapter 10: Variably protease-sensitive prionopathy. In: Pocchiari M., Manson J., editors. Handbook of Clinical Neurology. Volume 153. Elsevier; Amsterdam, The Netherlands: 2018. pp. 175–190. PubMed DOI

Zou W.Q., Puoti G., Xiao X., Yuan J., Qing L., Cali I., Shimoji M., Langeveld J.P., Castellani R., Notari S., et al. Variably protease-sensitive prionopathy: A new sporadic disease of the prion protein. Ann. Neurol. 2010;68:162–172. doi: 10.1002/ana.22094. PubMed DOI PMC

Aizpurua M., Selvackadunco S., Yull H., Kipps C.M., Ironside J.W., Bodi I. Variably protease-sensitive prionopathy mimicking frontotemporal dementia. Neuropathology. 2019;39:135–140. doi: 10.1111/neup.12538. PubMed DOI PMC

Will R.G. Acquired prion disease: Iatrogenic CJD, variant CJD, kuru. Br. Med. Bulletin. 2003;66:255–265. doi: 10.1093/bmb/66.1.255. PubMed DOI

Moffatt S.L., Pollock G. Creutzfeldt-Jakob disease: Perceptions and realities of risk. Clin Exp. Ophthalmol. 2006;34:635–636. doi: 10.1111/j.1442-9071.2006.01387.x. PubMed DOI

Bonda D.J., Manjila S., Mehndiratta P., Khan F., Miller B.R., Onwuzulike K., Puoti G., Cohen M.L., Schonberger L.B., Cali I. Human prion diseases: Surgical lessons learned from iatrogenic prion transmission. Neurosurg. Focus. 2016;41:E10. doi: 10.3171/2016.5.FOCUS15126. PubMed DOI PMC

Brown P., Brandel J.P., Sato T., Nakamura Y., MacKenzie J., Will R.G. Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerg. Infect Dis. 2012;18:901–907. doi: 10.3201/eid1806.120116. PubMed DOI PMC

Will R.G., Matthews W.B. Evidence for case-to-case transmission of Creutzfeldt-Jakob disease. J. Neurol. Neurosurg. Psychiatry. 1982;45:235–238. doi: 10.1136/jnnp.45.3.235. PubMed DOI PMC

Hilton D.A. Pathogenesis and prevalence of variant Creutzfeldt-Jakob disease. J. Pathol. 2006;208:134–141. doi: 10.1002/path.1880. PubMed DOI

Sikorska B., Liberski P.P., Sobów T., Budka H., Ironside J.W. Ultrastructural study of florid plaques in variant Creutzfeldt-Jakob disease: A comparison with amyloid plaques in kuru, sporadic Creutzfeldt-Jakob disease and Gerstmann-Sträussler-Scheinker disease. Neuropathol. Appl. Neurobiol. 2009;35:46–59. doi: 10.1111/j.1365-2990.2008.00959.x. PubMed DOI

Zeidler M., Sellar R.J., Collie D.A., Knight R., Stewart G., Macleod M.A., Ironside J.W., Cousens S., Colchester A.C., Hadley D.M., et al. The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet. 2000;355:1412–1418. doi: 10.1016/S0140-6736(00)02140-1. PubMed DOI

Hill A.F., Butterworth R.J., Joiner S., Jackson G., Rossor M.N., Thomas D.J., Frosh A., Tolley N., Bell J.E., Spencer M., et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet. 1999;353:183–189. doi: 10.1016/S0140-6736(98)12075-5. PubMed DOI

Mok T., Jaunmuktane Z., Joiner S., Campbell T., Morgan C., Wakerley B., Golestani F., Rudge P., Mead S., Jäger H.R., et al. Variant Creutzfeldt-Jakob Disease in a Patient with Heterozygosity at PRNP Codon 129. N. Engl. J. Med. 2017;376:292–294. doi: 10.1056/NEJMc1610003. PubMed DOI

Collinge J. Molecular neurology of prion disease. J. Neurol. Neurosurg. Psychiatry. 2005;76:906–919. doi: 10.1136/jnnp.2004.048660. PubMed DOI PMC

Head M.W., Bunn T.J.R., Bishop M.T., McLoughlin V., Lowrie S., McKimmie C.S., Williams M.C., McCardle L., Mackenzie J., Knight R., et al. Prion protein heterogeneity in sporadic but not variant Creutzfeldt-Jakob disease: United Kingdom cases 1991–2002. Ann. Neurol. 2004;55:851–859. doi: 10.1002/ana.20127. PubMed DOI

Llewelyn C.A., Hewitt P.E., Knight R.S., Amar K., Cousens S., Mackenzie J. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet. 2004;363:417–421. doi: 10.1016/S0140-6736(04)15486-X. PubMed DOI

Gajdusek D.C., Zigas V. Degenerative disease of the central nervous system in New Guinea. The endemic occurrence of “kuru” in the native population. N. Engl. J. Med. 1957;257:974–978. doi: 10.1056/NEJM195711142572005. PubMed DOI

Alpers M.P. The epidemiology of kuru: Monitoring the epidemic from its peak to the end. Philos. Trans. R. Soc. B. 2008;363:3707–3713. doi: 10.1098/rstb.2008.0071. PubMed DOI PMC

Beasley A. The promised medicine: Fore reflections on the scientific investigation of kuru. Oceania. 2006;76:186–202. doi: 10.1002/j.1834-4461.2006.tb03044.x. DOI

Liberski P.P., Gajos A., Sikorska B., Lindenbaum S. Kuru, the First Human Prion Disease. Viruses. 2019;11:232. doi: 10.3390/v11030232. PubMed DOI PMC

Le Bouvier G. Slow, Latent, and Temperate Virus Infections. Yale J. Biol. Med. 1967;39:83–84.

Beck E., Daniel P.M. Prion diseases from a neuropathologist’s perspective. In: Prusiner S.B., Collinge J., Powell J., Anderton B., editors. Prion Diseases of Humans and Animals. Ellis Horwood; New York, NY, USA: London, UK: Toronto, ON, Canada: Sydney, Australia: Singapore: 1993. pp. 63–65.

Ladogana A., Kovacs G.G. Handbook of Clinical Neurology. Volume 153. Elsevier; Amsterdam, The Netherlands: 2018. Chapter 13: Genetic Creutzfeldt-Jakob disease; pp. 219–242. PubMed DOI

Gao L.P., Shi Q., Xiao K., Wang J., Zhou W., Chen C., Dong X.P. The genetic Creutzfeldt-Jakob disease with E200K mutation: Analysis of clinical, genetic and laboratory features of 30 Chinese patients. Sci. Rep. 2019;9:1836. doi: 10.1038/s41598-019-38520-y. PubMed DOI PMC

Kovács G.G., Puopolo M., Ladogana A., Pocchiari M., Budka H., van Duijn C., Collins S.J., Boyd A., Giulivi A., Coulthart M., et al. EUROCJD. Genetic prion disease: The EUROCJD experience. Hum. Genet. 2005;118:166–174. doi: 10.1007/s00439-005-0020-1. PubMed DOI

Rohan Z., Rusina R., Marešová M., Matěj R. Lidská prionová onemocnění v České republice. Epidemiol. Mikrobiol. Imunol. 2015;64:115–120. PubMed

Nozaki I., Hamaguchi T., Sanjo N., Noguchi-Shinohara M., Sakai K., Nakamura Y., Sato T., Kitamoto T., Mizusawa H., Moriwaka F., et al. Prospective 10-year surveillance of human prion diseases in Japan. Brain. 2010;133:3043–3057. doi: 10.1093/brain/awq216. PubMed DOI

Chapman J., Ben-Israel J., Goldhammer Y., Korczyn A.D. The risk of developing Creutzfeldt-Jakob disease in subjects with the PRNP gene codon 200 point mutation. Neurology. 1994;44:1683–1686. doi: 10.1212/WNL.44.9.1683. PubMed DOI

Liberski P.P. Gerstmann-Sträussler-Scheinker disease. Adv. Exp. Med. Biol. 2012;724:128–137. PubMed

Gambetti P., Kong Q., Zou W., Parchi P., Chen S.G. Sporadic and familial CJD: Classification and characterisation. Br. Med. Bull. 2003;66:213–239. doi: 10.1093/bmb/66.1.213. PubMed DOI

Ghetti B., Tagliavini F., Takao M., Bugiani O., Piccardo P. Hereditary prion protein amyloidoses. Clin. Lab. Med. 2003;23:65–85. doi: 10.1016/S0272-2712(02)00064-1. PubMed DOI

Galatioto S., Ruggeri D., Gullotta F. Gerstmann-Sträussler-Scheinker syndrome in a Sicilian patient. Neuropathological aspects. Pathologica. 1995;87:659–665. PubMed

Keller J., Eliasova I., Parobkova E., Smetakova M., Musova Z., Rusina R. Clinical Variability in P102L Gerstmann-Sträussler-Scheinker Syndrome. Ann. Neurol. 2019;86:643–652. doi: 10.1002/ana.25579. PubMed DOI

Jansen C., Voet W., Head M.W., Parchi P., Yull H., Verrips A., Wesseling P., Meulstee J., Baas F., van Gool W.A., et al. A novel seven-octapeptide repeat insertion in the prion protein gene (PRNP) in a Dutch pedigree with Gerstmann-Sträussler-Scheinker disease phenotype: Comparison with similar cases from the literature. Acta Neuropathol. 2011;121:59–68. doi: 10.1007/s00401-010-0656-3. PubMed DOI PMC

Medori R., Tritschler H.J., LeBlanc A., Villare F., Manetto V., Chen H.Y., Xue R., Leal S., Montagna P., Cortelli P., et al. Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene. N. Engl. J. Med. 1992;326:444–449. doi: 10.1056/NEJM199202133260704. PubMed DOI PMC

Llorens F., Zarranz J.J., Fischer A., Zerr I., Ferrer I. Fatal Familial Insomnia: Clinical Aspects and Molecular Alterations. Curr Neurol. Neurosci. Rep. 2017;17:30. doi: 10.1007/s11910-017-0743-0. PubMed DOI

Geschwind M.D., Shu H., Haman A., Sejvar J.J., Miller B.L. Rapidly progressive dementia. Ann. Neurol. 2008;64:97–108. doi: 10.1002/ana.21430. PubMed DOI PMC

Chitravas N., Jung R.S., Kofskey D.M., Blevins J.E., Gambetti P., Leigh R.J., Cohen M.L. Treatable neurological disorders misdiagnosed as Creutzfeldt–Jakob disease. Ann. Neurol. 2011;70:437–444. doi: 10.1002/ana.22454. PubMed DOI PMC

Poser S., Mollenhauer B., Kraubeta A., Zerr I., Steinhoff B.J., Schroeter A., Finkenstaedt M., Schulz-Schaeffer W.J., Kretzschmar H.A., Felgenhauer K. How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. Brain. 1999;122:2345–2351. doi: 10.1093/brain/122.12.2345. PubMed DOI

Saiz A., Graus F., Dalmau J., Pifarré A., Marin C., Tolosa E. Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. Ann. Neurol. 1999;46:774–777. doi: 10.1002/1531-8249(199911)46:5<774::AID-ANA14>3.0.CO;2-N. PubMed DOI

Fermo O.P., Izbudak I., Sutter R., Venkatesan A., Kaplan P.W., Probasco J.C. Autoimmune encephalitis mimicking Creutzfeldt–Jakob disease. Neurol. Clin. Pract. 2014;4:493–495. doi: 10.1212/CPJ.0000000000000065. PubMed DOI PMC

World Health Organization WHO Manual for Surveillance of Human Transmissible Spongiform Encephalopathies, Including Variant Creutzfeldt-Jakob Disease. World Health Organization. 2003. [(accessed on 3 February 2021)]. Available online: https://apps.who.int/iris/handle/10665/42656.

Gauthier A.C., Baehring J.M. Hashimoto’s encephalopathy mimicking Creutzfeldt–Jakob disease. J. Clin. Neurosci. 2017;35:72–73. doi: 10.1016/j.jocn.2016.09.019. PubMed DOI

Mead S., Rudge P. CJD mimics and chameleons. Pract. Neurol. 2017;17:113–121. doi: 10.1136/practneurol-2016-001571. PubMed DOI PMC

Lanata S., Gambetti P., Geschwind M. Wernicke-Korsakoff Syndrome Mimicking Sporadic Jakob-Creutzfeldt Disease. Neurology. 2014;82:P5.235.

Rusina R., Krajcovicova L., Srpova B., Matěj R. Metastatic intracranial spread of adenocarcinoma mimicking Creutzfeldt-Jakob disease in two cases. Rev. Neurol. 2021 doi: 10.1016/j.neurol.2020.12.009. In press. PubMed DOI

Toledo J.B., Brettschneider J., Grossman M., Arnold S.E., Hu W.T., Xie S.X., Lee V.M., Shaw L.M., Trojanowski J.Q. CSF biomarkers cutoffs: The importance of coincident neuropathological diseases. Acta Neuropathol. 2012;124:23–35. doi: 10.1007/s00401-012-0983-7. PubMed DOI PMC

Foote M., Zhou Y. 14-3-3 proteins in neurological disorders. Int. J. Biochem. Mol. Biol. 2012;3:152–164. PubMed PMC

Satoh K., Tobiume M., Matsui Y., Mutsukura K., Nishida N., Shiga Y., Eguhchi K., Shirabe S., Sata T. Establishment of a standard 14-3-3 protein assay of cerebrospinal fluid as a diagnostic tool for Creutzfeldt-Jakob disease. Lab. Investig. 2010;90:1637–1644. doi: 10.1038/labinvest.2009.68. PubMed DOI

Cuadrado-Corrales N., Jiménez-Huete A., Albo C., Hortigüela R., Vega L., Cerrato L., Sierra-Moros M., Rábano A., de Pedro-Cuesta J., Calero M. Impact of the clinical context on the 14-3-3 test for the diagnosis of sporadic CJD. BMC Neurol. 2006;6:25. doi: 10.1186/1471-2377-6-25. PubMed DOI PMC

Skillbäck T., Rosén C., Asztely F., Mattsson N., Blennow K., Zetterberg H. Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: Results from the Swedish Mortality Registry. JAMA Neurol. 2014;71:476–483. doi: 10.1001/jamaneurol.2013.6455. PubMed DOI

Rohan Z., Smetakova M., Kukal J., Rusina R., Matěj R. Proteinase-activated receptor 2 and disease biomarkers in cerebrospinal fluid in cases with autopsy-confirmed prion diseases and other neurodegenerative diseases. BMC Neurol. 2015;31:50. doi: 10.1186/s12883-015-0300-x. PubMed DOI PMC

Bruzova M., Rusina R., Stejskalova Z., Matěj R. Autopsy-diagnosed neurodegenerative dementia cases support the use of cerebrospinal fluid protein biomarkers in the diagnostic work-up. Sci. Rep. 2021 doi: 10.1038/s41598-021-90366-5. In press. PubMed DOI PMC

Green A.J.E. RT-QuIC: A new test for sporadic CJD. Pract. Neurol. 2019;19:49–55. doi: 10.1136/practneurol-2018-001935. PubMed DOI PMC

Orrú C.D., Groveman B.R., Hughson A.G., Zanusso G., Coulthart M.B., Caughey B. Rapid and sensitive RT-QuIC detection of human Creutzfeldt-Jakob disease using cerebrospinal fluid. mBio. 2015;6:e02451-14. doi: 10.1128/mBio.02451-14. PubMed DOI PMC

Wilham J.M., Orrú C.D., Bessen R.A., Atarashi R., Sano K., Race B., Meade-White K.D., Taubner L.M., Timmes A., Caughey B. Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays. PLoS Pathog. 2021;6:e1001217. doi: 10.1371/journal.ppat.1001217. PubMed DOI PMC

Bongianni M., Orrù C., Groveman B.R., Sacchetto L., Fiorini M., Tonoli G., Triva G., Capaldi S., Testi S., Ferrari S., et al. Diagnosis of Human Prion Disease Using Real-Time Quaking-Induced Conversion Testing of Olfactory Mucosa and Cerebrospinal Fluid Samples. JAMA Neurol. 2017;74:155–162. doi: 10.1001/jamaneurol.2016.4614. PubMed DOI

Foutz A., Appleby B.S., Hamlin C., Liu X., Yang S., Cohen Y., Chen W., Blevins J., Fausett C., Wang H., et al. Diagnostic and prognostic value of human prion detection in cerebrospinal fluid. Ann Neurol. 2017;81:79–92. doi: 10.1002/ana.24833. PubMed DOI PMC

Franceschini A., Baiardi S., Hughson A.G., McKenzie N., Moda F., Rossi M., Capellari S., Green A., Giaccone G., Caughey B., et al. High diagnostic value of second generation CSF RT-QuIC across the wide spectrum of CJD prions. Sci. Rep. 2017;7:10655. doi: 10.1038/s41598-017-10922-w. PubMed DOI PMC

Parchi P., Strammiello R., Notari S., Giese A., Langeveld J.P., Ladogana A., Zerr I., Roncaroli F., Cras P., Ghetti B., et al. Incidence and spectrum of sporadic Creutzfeldt-Jakob disease variants with mixed phenotype and co-occurrence of PrPSc types: An updated classification. Acta Neuropathol. 2009;118:659–671. doi: 10.1007/s00401-009-0585-1. PubMed DOI PMC

Parchi P., de Boni L., Saverioni D., Cohen M.L., Ferrer I., Gambetti P., Gelpi E., Giaccone G., Hauw J.J., Höftberger R., et al. Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: An inter-rater study among surveillance centres in Europe and USA. Acta Neuropathol. 2012;124:517–529. doi: 10.1007/s00401-012-1002-8. PubMed DOI PMC

Armitage W., Tullo A., Ironside J. Risk of Creutzfeldt–Jakob disease transmission by ocular surgery and tissue transplantation. Eye. 2009;23:1926–1930. doi: 10.1038/eye.2008.381. PubMed DOI

Mehta J.S., Franks W.A. The sclera, the prion, and the ophthalmologist. Br. J. Ophthalmol. 2002;86:587–592. doi: 10.1136/bjo.86.5.587. PubMed DOI PMC

Sbírka Zákonů: Předpis 97/2019 Sb. [(accessed on 15 January 2021)]. Available online: https://www.psp.cz/sqw/sbirka.sqw?cz=97&r=2019.

Jirsova K., Krabcova I., Novakova J., Hnathova I., Koukolik F., Kubesova B., Netukova M., Matěj R. The assessment of pathogenic prions in the brains of eye tissue donors Cesk Slov Neurol: 2-years experience in the Czech Republic. Cornea. 2010;29:996–999. doi: 10.1097/ICO.0b013e3181cc7b37. PubMed DOI

Mitrová E., Belay G. Creutzfeldt-Jakob disease with E200K mutation in Slovakia: Characterization and development. Acta Virol. 2002;46:31–39. PubMed

Mitrová E., Cernák A., Slivarichová D., Koščová S., Bernovská V., Cernák M. Experience with preventive genetic testing of corneal donors in slovakia. Cornea. 2011;30:987–990. doi: 10.1097/ICO.0b013e3182035ac1. PubMed DOI

Sikora J., Srbová A., Koukolík F., Matěj R. Retrospective sequence analysis of the human PRNP gene from the formaldehyde-fixed paraffin-embedded tissues: Report of two cases of Creutzfeldt-Jakob disease. Folia Microbiol. 2006;51:619–625. doi: 10.1007/BF02931629. PubMed DOI

Rusina R., Fiala J., Holada K., Matějčková M., Nováková J., Ampapa R., Koukolík F., Matěj R. Gerstmann-Sträussler-Scheinker syndrome with the P102L pathogenic mutation presenting as familial Creutzfeldt-Jakob disease: A case report and review of the literature. Neurocase. 2013;19:41–53. doi: 10.1080/13554794.2011.654215. PubMed DOI

Matěj R., Kovacs G.G., Johanidesová S., Keller J., Matějčková M., Nováková J., Sigut V., Keller O., Rusina R. Genetic Creutzfeldt-Jakob disease with R208H mutation presenting as progressive supranuclear palsy. Mov. Disord. 2012;27:476–479. doi: 10.1002/mds.24002. PubMed DOI

Rohan Z., Parobkova E., Johanidesova S., Koukolik F., Matěj R., Rusina R. Human Prion Diseases in the Czech Republic—10 Years of Experience with the Diagnosis. Cesk. Slov. Neurol. Neurochir. 2013;76:300–306.

Klug G.M., Wand H., Simpson M., Boyd A., Law M., Masters C.L., Matěj R., Howley R., Farrell M., Breithaupt M., et al. Intensity of human prion disease surveillance predicts observed disease incidence. J. Neurol. Neurosurg. Psychiatry. 2013;84:1372–1377. doi: 10.1136/jnnp-2012-304820. PubMed DOI

Kovacs G.G., Rahimi J., Ströbel T., Lutz M.I., Regelsberger G., Streichenberger N., Perret-Liaudet A., Höftberger R., Liberski P.P., Budka H., et al. Tau pathology in Creutzfeldt-Jakob disease revisited. Brain Pathol. 2017;27:332–344. doi: 10.1111/bpa.12411. PubMed DOI PMC

Parobkova E., van der Zee J., Dillen L., Van Broeckhoven C., Rusina R., Matěj R. Sporadic Creutzfeldt-Jakob Disease and Other Proteinopathies in Comorbidity. Front. Neurol. 2020;11:596108. doi: 10.3389/fneur.2020.596108. PubMed DOI PMC

Biomarkers Analysis and Clinical Manifestations in Comorbid Creutzfeldt-Jakob Disease: A Retrospective Study in 215 Autopsy Cases

Extracellular Prion Protein Aggregates in Nine Gerstmann-Sträussler-Scheinker Syndrome Subjects with Mutation P102L: A Micromorphological Study and Comparison with Literature Data